GD2 and GD3 synthase: novel drug targets for cancer therapy.
Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)-the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2-abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.
Department of Translational Molecular Pathology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Nathalie
N
Sphyris
Department of Translational Molecular Pathology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Tapasree Roy
TR
Sarkar
Department of Leukemia; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Venkata L
VL
Battula
Department of Leukemia; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Michael
M
Andreeff
Department of Translational Molecular Pathology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; Metastasis Research Center; The University of Texas MD Anderson Cancer Center; Houston, TX USA; Center for Stem Cells and Developmental Biology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
Sendurai A
SA
Mani
EMT; GD2; GD3S; cancer stem cells; metastasis